- Home
- MSTR vs VRTX Comparison
MSTR vs VRTX Comparison
Compare MSTR & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSTR
- VRTX
- Stock Information
- Founded
- MSTR 1989
- VRTX 1989
- Country
- MSTR United States
- VRTX United States
- Employees
- MSTR N/A
- VRTX N/A
- Industry
- MSTR Computer Software: Prepackaged Software
- VRTX EDP Services
- Sector
- MSTR Technology
- VRTX Technology
- Exchange
- MSTR Nasdaq
- VRTX Nasdaq
- Market Cap
- MSTR 106.8B
- VRTX 115.6B
- IPO Year
- MSTR 1998
- VRTX 1991
- Fundamental
- Price
- MSTR $403.00
- VRTX $471.98
- Analyst Decision
- MSTR Strong Buy
- VRTX Buy
- Analyst Count
- MSTR 11
- VRTX 25
- Target Price
- MSTR $469.27
- VRTX $509.00
- AVG Volume (30 Days)
- MSTR 12.0M
- VRTX 1.0M
- Earning Date
- MSTR 07-31-2025
- VRTX 08-04-2025
- Dividend Yield
- MSTR N/A
- VRTX N/A
- EPS Growth
- MSTR N/A
- VRTX N/A
- EPS
- MSTR N/A
- VRTX N/A
- Revenue
- MSTR $459,276,000.00
- VRTX $11,099,700,000.00
- Revenue This Year
- MSTR $1.77
- VRTX $10.43
- Revenue Next Year
- MSTR $3.43
- VRTX $10.81
- P/E Ratio
- MSTR N/A
- VRTX N/A
- Revenue Growth
- MSTR N/A
- VRTX 8.98
- 52 Week Low
- MSTR $102.40
- VRTX $377.85
- 52 Week High
- MSTR $543.00
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- MSTR 44.97
- VRTX 55.65
- Support Level
- MSTR $390.41
- VRTX $460.55
- Resistance Level
- MSTR $417.01
- VRTX $480.00
- Average True Range (ATR)
- MSTR 14.88
- VRTX 8.41
- MACD
- MSTR -5.57
- VRTX -0.29
- Stochastic Oscillator
- MSTR 10.34
- VRTX 63.83
About MSTR MicroStrategy Incorporated
Strategy is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provide industry AI-powered enterprise analytics software.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.